Therapeutic Adalimumab antibody from the original Humira® and biosimilar commercial drugs.
Product Batch | Therapeutic Expiry Date | Brand & Origin | Amount per Aliquot | Select Quantity | Discount | Price per Aliquot | |
|---|---|---|---|---|---|---|---|
2026.02 |
Humira® DE |
4 mg |
Max: 20
Min: 1
Step: 1
|
338,00 €/aliquot
|
|||
2018.12 |
Humira® LV |
4 mg |
Max: 10
Min: 1
Step: 1
|
451,00 €
/aliquot
|
|||
2019.03 |
Humira® DE |
4 mg |
Max: 9
Min: 1
Step: 1
|
451,00 €
/aliquot
|
|||
2019.03 |
Humira® DE |
4 mg |
Max: 5
Min: 1
Step: 1
|
451,00 €
/aliquot
|
|||
2019.07 |
Humira® DE |
4 mg |
Max: 6
Min: 1
Step: 1
|
451,00 €
/aliquot
|
Product Batch | Therapeutic Expiry Date | Brand & Origin | Amount per Aliquot | Select Quantity | Discount | Price per Aliquot | |
|---|---|---|---|---|---|---|---|
2021.12 |
Amgevita® DE |
2 mg |
Max: 10
Min: 1
Step: 1
|
304,00 €
/aliquot
|
|||
2023.02 |
Hulio® DE |
2 mg |
Max: 10
Min: 1
Step: 1
|
304,00 €
/aliquot
|
|||
2023.10 |
Hukyndra® DE |
2 mg |
Max: 10
Min: 1
Step: 1
|
354,00 €
/aliquot
|
|||
2024.02 |
Yuflyma® DE |
4 mg |
Max: 3
Min: 1
Step: 1
|
354,00 €
/aliquot
|
|||
2023.10 |
Idacio® DE |
2 mg |
Max: 10
Min: 1
Step: 1
|
355,00 €
/aliquot
|
|||
2023.10 |
Imraldi® DE |
2 mg |
Max: 10
Min: 1
Step: 1
|
304,00 €
/aliquot
|
|||
2024.06 |
Hyrimoz® DE |
2 mg |
Max: 10
Min: 1
Step: 1
|
304,00 €
/aliquot
|
Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API).
Here you will find the product information for the reference product.
| Drug Name | Humira® |
| INN | Adalimumab |
| API Type | Adalimumab is a recombinant human monoclonal antibody expressed in Chinese Hamster Ovary cells. |
| Pharmacotherapeutic Group | Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors. |
| ATC Code | L04AB04 |
| Target of Antibody | TNF alpha |
| General Function | Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of0.1-0.2 nM). |
| Short Description | |
| Pharmacodynamic Properties (Mechanism of Action; Source EMA document) | Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. |
| Pharmacodynamic Properties (Pharmacodynamic Effects; Source EMA document) | Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM). |
| Original License Holder | AbbVie Biotechnology GmbH Knollstrasse 67061 Ludwigshafen Germany |
| Marketing Authorisation Numbers | EU/1/03/256/022 |
| Marketing Authorisation Holder | AbbVie Ltd Maidenhead SL6 4UB United Kingdom |
| Name of the Manufacturer of the Biological Active Substance | AbbVie Bioresearch Center 100 Research Drive Worcester MA 01605 USA |
| Name and Address of the Manufacturer(s) Responsible for Batch Release | AbbVie Biotechnology GmbH Knollstrasse 67061 Ludwigshafen Germany |
| Max Shelf Life | 24 months |
| Storage Conditions | 2°C – 8°C |
| List of Excipients | Mannitol Polysorbate 80 |
Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!
Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!
Receive a confidential, non-binding quote for the molecule(s) you choose.
Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.